AL 335/odalasvir/simeprevir - Janssen/Medivir

Drug Profile

AL 335/odalasvir/simeprevir - Janssen/Medivir

Alternative Names: AL-335/odalasvir/simeprevir - Janssen/Medivir; JNJ-4178; odalasvir/simeprevir/AL-335 - Janssen/Medivir; simeprevir/AL-335/odalasvir - Janssen/Medivir

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Janssen; Medivir AB
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 24 Apr 2017 Janssen Research & Development completes enrolment in the OMEGA-1 phase IIb trial for Hepatitis C in Belgium, Canada, Germany, Poland, Singapore and Spain
  • 22 Apr 2017 Efficacy data from phase II Study 604 in Hepatitis C presented at the European Association for the Study of the Liver (EASL-2017)
  • 04 Apr 2017 Janssen Research & Development initiates enrolment in a long-term follow-up trial for Hepatitis C (In adults, In the elderly) in New Zealand and Canada (NCT03099135)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top